GLP-1 persistence: What semaglutide data reveals about patient behavior
As the new year begins, many patients refocus on weight management and long-term health goals. At...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
The evolution of heart failure treatment and research Heart failure remains one of the most...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
As the new year begins, many patients refocus on weight management and long-term health goals. At the same time, GLP-1 drugs have reshaped the obesity treatment landscape.1,2 With semaglutide and other GLP-1 medications in high demand for weight loss...